#London #United Kingdom #Hikma #KLOXXADO #Emergent BioSolutions

Hikma and Emergent BioSolutions Join Forces

Hikma Pharmaceuticals PLC, a prominent global pharmaceutical company, has announced a significant new partnership with Emergent BioSolutions, aimed at tackling the opioid crisis through improved access to life-saving naloxone treatment. This collaboration is focused on the KLOXXADO® (naloxone HCl) 8 mg nasal spray, which serves as an emergency intervention for opioid overdoses.

Partnership Overview

The agreement, effective for six years, grants Emergent exclusive rights to market and sell KLOXXADO® nasal spray in the United States and Canada. This is a pivotal moment as the ongoing opioid epidemic continues to impact communities across these regions. KLOXXADO® was granted FDA approval in April 2021, joining the ranks of essential medications needed to combat opioid overdoses that exhibit respiratory and central nervous system depression.

Emergent BioSolutions is already familiar with the naloxone market, distributing NARCAN® Nasal Spray, which holds the distinction of being the first FDA-approved over-the-counter naloxone product. The synergy of combining Hikma's advanced manufacturing capabilities with Emergent's established commercial expertise aims to enhance the availability of this critical medication.

Hafrun Fridriksdottir, President of Hikma's Generics division, expressed enthusiasm about the partnership, stating: "We are thrilled to be partnering with Emergent, who have deep experience in getting lifesaving naloxone nasal spray into the hands of those who can use it to help save lives." She emphasized that this partnership will leverage Hikma's high-quality production facility in Columbus, Ohio, to ensure the continuous supply of KLOXXADO® nasal spray.

Importance of KLOXXADO®

Naloxone is a critical medication that can rapidly reverse an overdose caused by opioids. It works by restoring normal breathing in patients who have overdosed and exhibits symptoms such as extreme sedation or respiratory distress. KLOXXADO® is particularly well-suited for immediate emergency situations, designed for those who may encounter opioid overdose scenarios.

It's not only for adults; it’s also indicated for pediatric patients, making it widely useful. Importantly, KLOXXADO® is not a substitute for emergency medical care and should be administered promptly in overdose situations, highlighting the importance of having access to this life-saving drug.

Continuing Production and Support

Under the partnership terms, Hikma remains committed to producing KLOXXADO® while Emergent manages its sales and marketing strategies. This collaborative approach aims to enhance outreach and training initiatives surrounding naloxone usage among families, caregivers, and healthcare providers. Hikma is also dedicated to ensuring that other forms of naloxone, including vials and syringes, remain accessible to patients and the public health community, ensuring broader distribution of this essential medication.

A Commitment to Health

Hikma's mission focuses on improving health outcomes globally, and this partnership reinforces that commitment as they work together to deliver innovative and essential healthcare solutions. The partnership not only addresses emergency pharmacological needs but also aids efforts to mitigate the broader public health crisis posed by opioid overdoses.

Future Implications

As the opioid crisis continues to hold a firm grip on North America, partnerships like the one formed between Hikma and Emergent BioSolutions are vital. Their efforts could potentially save countless lives and foster significant changes in how communities respond to the challenge of opioid addiction and overdose emergencies.

For more information about KLOXXADO® and its uses, or to stay updated on further developments from Hikma Pharmaceuticals, visit their official website.